Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 8/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 8/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30377778 | 0.81 | OPRM1 (0.53) | PDE7AMDM2OPRM1OPRK1OPRL1 | |
| SCHEMBL7468658 | 0.76 | PDE7A (0.45) | PDE7AOPRM1OPRK1OPRL1AKR1B1 | |
| SCHEMBL3964443 | 0.75 | MDM2 (0.52) | TP53MDM2 | |
| SCHEMBL7466189 | 0.74 | IDO1 (0.58) | PDE7ATP53OPRM1OPRK1OPRL1 | |
| SCHEMBL1320808 | 0.73 | MDM2 (0.43) | PDE7ATP53MDM2PKMCMA1 | |
| SCHEMBL3967711 | 0.71 | BRD4 (0.47) | PDE7ATP53MDM2PKMCMA1 | |
| SCHEMBL7465910 | 0.71 | MEN1 (0.43) | PDE7AGHSROPRM1OPRK1OPRL1 | |
| SCHEMBL1320009 | 0.70 | MDM2 (0.57) | TP53MDM2PKM | |
| SCHEMBL5344885 | 0.70 | AHR (0.46) | PDE7ATP53MDM2PKMCMA1 | |
| SCHEMBL3966441 | 0.70 | BRD4 (0.46) | PDE7ATP53MDM2PKMCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058269-B2 | rac-6-chloro-3-(3-chloro-benzyl)-3-(3-isopropoxy-phenylamino)-1,3-dihydro-indol-2-one; murine double minute (MDM2 ) oncogene inhibitor; feedback control loop of p53 mutant cells; inhibit the interaction between p53 and MDM2 proteins | HOFFMAN-LA ROCHE INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058269-B2 | rac-6-chloro-3-(3-chloro-benzyl)-3-(3-isopropoxy-phenylamino)-1,3-dihydro-indol-2-one; murine double minute (MDM2 ) oncogene inhibitor; feedback control loop of p53 mutant cells; inhibit the interaction between p53 and MDM2 proteins | HOFFMAN-LA ROCHE INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058269-B2 | rac-6-chloro-3-(3-chloro-benzyl)-3-(3-isopropoxy-phenylamino)-1,3-dihydro-indol-2-one; murine double minute (MDM2 ) oncogene inhibitor; feedback control loop of p53 mutant cells; inhibit the interaction between p53 and MDM2 proteins | HOFFMAN-LA ROCHE INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2066318-B1 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2010-05-12 | — | — | EP | disclosed |
| EP-2066318-B1 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2010-05-12 | — | — | EP | disclosed |
| EP-2066318-A2 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20080081810-A1 | OXINDOLE DERIVATIVES | CHEN LI | 2008-04-03 | — | — | US | disclosed |
| US-20080081810-A1 | OXINDOLE DERIVATIVES | CHEN LI | 2008-04-03 | — | — | US | disclosed |
| US-20080081810-A1 | OXINDOLE DERIVATIVES | CHEN LI | 2008-04-03 | — | — | US | disclosed |
| WO-2008034736-A2 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008034736-A2 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081810-A1 | OXINDOLE DERIVATIVES | CCNY, CCNI, RPS4Y1 | PDE7A 4827/4885TP53 219/4885MDM2 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.